RECRUITINGOBSERVATIONAL
DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
About This Trial
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
Who May Be Eligible (Plain English)
Case Inclusion:
- Subjects should have suspected or confirmed cancer of the upper genital tract.
- Participant will undergo surgery for tumour removal.
Control inclusion:
• Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Case Inclusion:
* Subjects should have suspected or confirmed cancer of the upper genital tract.
* Participant will undergo surgery for tumour removal.
Control inclusion:
• Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.
Locations (1)
Royal Victoria Hospital (Glen Site)
Montreal, Quebec, Canada